We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Venture Life Group Plc | LSE:VLG | London | Ordinary Share | GB00BFPM8908 | ORD 0.3P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 38.50 | 38.00 | 39.00 | 38.50 | 38.50 | 38.50 | 163,572 | 08:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Misc Retail Stores, Nec | 51.41M | 921k | 0.0072 | 53.47 | 48.92M |
Date | Subject | Author | Discuss |
---|---|---|---|
22/9/2022 10:27 | I think the cost of Ultradex, Dentyl & Pharmasource was around £14m (UltraDex - £5.8m Dentyl - £4.2m Pharmasource ~ £4m). Most of the £55-60m you quote was on BBIH and HICP (around £40m). I think it's true that they paid full whack for BBIH (if we are being generous) but I don't think the revenue run rate is lower than when they bought it, is it? You are probably right about Ultradex, Dentyl & Pharmasource, I don't know I haven't checked. But it's been a hard time during covid and with the current environment. | stemis | |
22/9/2022 09:57 | I'm aware they are differentiating between Ultradex, Dentyl & Pharmasource and the 2 most recent acquisitions. But strange to describe acquisitions made by the current CEO in 2016-2019 as 'legacy'. I estimate they spent £55-60m on the VLG brands/businesses with current total run rate of revenues lower than when those businesses were acquired. Seems pretty poor capital allocation. | cockerhoop | |
22/9/2022 09:31 | The company raised £36m at 90p to fund the purchase of BBIH and, even then, the open offer was scaled back. Those shares are now worth £11m. If one attributed that to the market's current valuation of BBIH (which I accept is a bit of stretch) then it looks a bit of a steal. Tough for those who paid 90p though... | stemis | |
22/9/2022 09:22 | "Hilarious they describe recent acquisitions made since 2016 as 'legacy products'" No, the two most recent acquisitions BBIH and HICP (which cost around £40m) aren't what they refer to as 'legacy revenues'. The two grew revenues by 9.5%. | stemis | |
22/9/2022 09:13 | Cannot understand drop as seemed a pretty good RNS | chique | |
22/9/2022 09:11 | Hilarious they describe recent acquisitions made since 2016 as 'legacy products'. They spent top dollar on those brands/businesses and have had no tangible success in developing them. | cockerhoop | |
22/9/2022 09:07 | will likely see more directors buys now results are out. They were buying in the mid 30s. | wooster4 | |
22/9/2022 09:07 | Looks like someone is selling in the background here. I thought the RNS was a bit flat, particularly sales of legacy products; however acquisitions doing well - this looks like a buy and hold to me. Most products are non discretionary self help health products so should be fairly solid, even in recessionary times. Buy at 28p, hold for 1-2 years and double your cash! | lammylover | |
22/9/2022 08:49 | Wonder if we have an institutional seller needing to be out. Simon Thompson should give us a good write up VLG is one of his favourites | basem1 | |
22/9/2022 08:46 | Not sure what game the market makers are playing here The early 28.7 trades were buys. Fishing for the bottom ? Any selling must stop soon ? Very frustrating indeed | basem1 | |
22/9/2022 08:38 | Venture Life offers a safe harbour in bear markets: | sev22 | |
22/9/2022 07:43 | Very encouraging outlook for H2 & beyond from OTC healthcare group Venture vlife today. All the analysis & commentary here. www.linkedin.com/fee | brummy_git | |
22/9/2022 07:03 | Agreed, organic growth looks v. healthy. Let's hope this is the start of the revival....DYOR | qs99 | |
22/9/2022 06:57 | Good results. | pngasef | |
26/8/2022 11:51 | IHC should be pretty bullet proof as supplying medical equipment to NHS and other global healthcare providers. If there is any sort of winter pandemic, you can bet your bottom dollar that IHC will pick up more ventilator business. Also specialised in neo natal baby care and no-one's going to cut expenditure here.. | lammylover | |
25/8/2022 15:05 | The IHC chart is a stinker though Lammy whichever way you cut it A big red flag for me despite the company looking in good shape Sorry for o/t | basem1 | |
25/8/2022 15:01 | IHC looks interesting ebitda/ nett cash against market cap look good will investigate further. A Rivaldo type stock. I have not seen if he posts there. | basem1 | |
25/8/2022 14:53 | I think there's a few funds bailing out of small AIM shares - yesterday IHC took a 10% drop, and later showed a 272k sell at 10% below market. No real explanation for it other than perhaps they are concerned that a lot of outfits are relying on a strong H2, which is a risk. I don't think its necessarily VLG weakness to inflation. Probably just a forced seller who then spooks others to sell at crazy daft prices.. | lammylover | |
25/8/2022 14:27 | I had 35000 so enough to be painful if I hadn't I'm around 2600 gbp up this year with them been in and out a few times with some largish holdings. Best watched for now, summer volumes and all that. Very cheap if trading is still in line | basem1 | |
25/8/2022 14:06 | Yes I just bailed luckily I didn’t have much but when it starts to drop on no news somebody knows something and those sales are big | csmwssk12hu | |
25/8/2022 14:00 | And I felt daft at selling at 33.7 a fortnight ago............. | basem1 | |
10/8/2022 13:29 | Jamie Constable of Singers talks positively about Venture Life here (starts 14:05) www.linkedin.com/fee | brummy_git | |
08/8/2022 11:51 | 35 about to go | csmwssk12hu | |
08/8/2022 09:48 | That 100k buy cleared the last of 34 | csmwssk12hu | |
08/8/2022 08:51 | Someone keeps buying 50000 shares at a time here | csmwssk12hu |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions